Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Interest & Investment Income: 2012-2025

Historic Interest & Investment Income for Enanta Pharmaceuticals (ENTA) over the last 11 years, with Sep 2025 value amounting to $2.1 million.

  • Enanta Pharmaceuticals' Interest & Investment Income fell 34.95% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.4 million, marking a year-over-year decrease of 36.07%. This contributed to the annual value of $9.4 million for FY2025, which is 36.07% down from last year.
  • Latest data reveals that Enanta Pharmaceuticals reported Interest & Investment Income of $2.1 million as of Q3 2025, which was down 9.58% from $2.3 million recorded in Q2 2025.
  • Enanta Pharmaceuticals' Interest & Investment Income's 5-year high stood at $4.7 million during Q3 2023, with a 5-year trough of $255,000 in Q1 2022.
  • In the last 3 years, Enanta Pharmaceuticals' Interest & Investment Income had a median value of $3.2 million in 2024 and averaged $3.1 million.
  • In the last 5 years, Enanta Pharmaceuticals' Interest & Investment Income skyrocketed by 883.72% in 2023 and then slumped by 39.83% in 2025.
  • Enanta Pharmaceuticals' Interest & Investment Income (Quarterly) stood at $258,000 in 2021, then soared by 284.88% to $993,000 in 2022, then soared by 332.83% to $4.3 million in 2023, then crashed by 34.88% to $2.8 million in 2024, then plummeted by 34.95% to $2.1 million in 2025.
  • Its last three reported values are $2.1 million in Q3 2025, $2.3 million for Q2 2025, and $2.3 million during Q1 2025.